Answers are grounded in this paper and cite their sources.
Prospective cohort study evaluates skin autofluorescence as a biomarker for chronic low back pain, suggesting potential clinical relevance.
[ABSTRACT] Low back pain is a globally debilitating health condition, but the mechanism of pain induction and perception in the context of low back pain remains unclear. Advanced glycation end-products (AGEs) have been reported as a possible biomarker of aging and we hypothesized that AGE accumulation is associated with chronic low back pain. The aim of this study was to determine whether AGEs measured by skin autofluorescence (SAF) can serve as a biomarker for chronic low back pain. 111 patients who visited the outpatient clinic were included in this prospective cohort study. They were divided into a chronic low back pain group (C group: 48 patients, mean age 52.2) and a group without low back pain (N group: 63 healthy volunteers, mean age 40.8). SAF was measured as a parameter of AGEs using an autofluorescence reader. Measurements of low back pain visual analog scale (VAS), presence of diabetes mellitus, and SAF were recorded, and correlations between VAS or diabetes mellitus and SAF were investigated. The C group had significantly higher SAF (2.20 vs 1.97, P=0.033) than the N group, whereas the SAF for diabetes mellitus patients was significantly higher (2.42 vs 1.97, P=0.003) than subjects without diabetes mellitus. SAF had no correlation with VAS (P=0.190). From multiple logistic regression analysis, SAF (OR=1.177, P=0.04) was identified as risk factors for chronic low back pain. SAF may serve as a biomarker for chronic low back pain.
No takes yet. Share an insight, caveat, or question.
Umimura et al. (2021) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: